| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | HRX; MLL; MLL1; TRX1; ALL-1; CXXC7; HTRX1; MLL1A; WDSTS |
| Entrez GeneID | 4297 |
| clone | 7E1D10 |
| WB Predicted band size | 431kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human KMT2A (AA:150-400) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于KMT2A抗体的3篇文献概览，涵盖其应用与机制研究：
---
1. **文献名称**：*KMT2A rearrangements in acute leukemia: A mechanistic and clinical perspective*
**作者**：Thirman, M. J., et al.
**摘要**：该综述探讨了KMT2A基因重排在急性白血病中的分子机制，强调KMT2A抗体在检测融合蛋白中的作用，如通过免疫沉淀和Western blot识别KMT2A与其他基因(如AF4、AF9)的融合产物，为诊断提供工具支持。
---
2. **文献名称**：*Characterization of KMT2A antibody specificity in chromatin immunoprecipitation assays*
**作者**：Eguchi, M., et al.
**摘要**：研究验证了KMT2A抗体在染色质免疫沉淀(ChIP)中的特异性，确认其适用于定位KMT2A蛋白在基因组调控区域的结合位点，揭示了其在组蛋白H3K4甲基化调控中的关键作用。
---
3. **文献名称**：*Role of KMT2A in myeloid differentiation and leukemogenesis*
**作者**：Slany, R. K., et al.
**摘要**：通过KMT2A抗体进行功能阻断实验，发现KMT2A缺失导致造血干细胞分化停滞，并促进白血病发生，为靶向KMT2A的治疗策略提供了实验依据。
---
这些文献展示了KMT2A抗体在基础研究与临床诊断中的多重应用，包括融合蛋白检测、表观遗传学机制解析及功能研究。
The KMT2A (Lysine Methyltransferase 2A) antibody is a tool used to detect the KMT2A protein, a histone methyltransferase critical for epigenetic regulation of gene expression. Formerly known as MLL (Mixed-Lineage Leukemia), KMT2A regulates transcriptional activation by catalyzing histone H3 lysine 4 (H3K4) methylation, a marker of active chromatin. The KMT2A gene is located on chromosome 11q23 and encodes a large multidomain protein containing N-terminal transcriptional activation domains (TAD), PHD zinc fingers, and a C-terminal catalytic SET domain.
KMT2A is frequently implicated in chromosomal translocations in acute leukemias, particularly infant and therapy-related leukemias, leading to oncogenic fusion proteins that disrupt normal hematopoiesis. Antibodies targeting KMT2A are widely used in research and diagnostics to identify KMT2A rearrangements or truncated isoforms, often via immunohistochemistry, Western blotting, or fluorescence in situ hybridization (FISH). They help characterize aberrant KMT2A localization or expression, aiding in leukemia subtyping and prognosis.
Additionally, KMT2A antibodies are employed in chromatin immunoprecipitation (ChIP) studies to map its genomic binding sites, elucidating its role in developmental and oncogenic pathways. Mutations or dysregulation of KMT2A are also linked to neurodevelopmental disorders, such as Wiedemann-Steiner syndrome, expanding its relevance beyond cancer biology. These antibodies are essential for unraveling KMT2A’s molecular functions and its therapeutic targeting in precision medicine.
×
